Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 300 of 436 entries
View as:

Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics

Phase: N/A Priority: Normal
NCT ID: NCT04682054 Org: User:
Start: 01/15/21 End: 12/31/21 Due: 12/31/22

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)

Phase: N/A Priority: Normal
NCT ID: NCT06225713 Org: User:
Start: 02/02/24 End: 12/31/24 Due: 12/31/25

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT04052152 Org: User:
Start: 06/10/19 End: 12/30/21 Due: 12/30/22

Effects of an Information-Based Discharge Service on Preterm Infants, Parents, and Hospitals

Phase: N/A Priority: Normal
NCT ID: NCT06613386 Org: User:
Start: 10/31/24 End: 03/31/25 Due: 03/31/26

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06696742 Org: User:
Start: 02/01/24 End: 02/01/29 Due: 02/01/30

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06504875 Org: User:
Start: 07/10/24 End: 07/10/27 Due: 07/10/28

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06479460 Org: User:
Start: 03/08/24 End: 03/31/26 Due: 03/31/27

Diagnostic Performance of a Novel Ferumoxytol-Enhanced Magnetic Resonance Angiography/ Venography on Panvascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT06136806 Org: User:
Start: 02/23/24 End: 01/30/25 Due: 01/30/26

Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging

Phase: N/A Priority: Normal
NCT ID: NCT05045872 Org: User:
Start: 09/17/21 End: 09/03/24 Due: 09/03/25

Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06613399 Org: User:
Start: 01/01/25 End: 12/31/27 Due: 12/31/28

Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink

Phase: N/A Priority: Normal
NCT ID: NCT06551298 Org: User:
Start: 10/01/24 End: 08/08/25 Due: 08/08/26

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06555471 Org: User:
Start: 08/06/24 End: 12/31/27 Due: 12/31/28

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Phase: N/A Priority: Normal
NCT ID: NCT06394791 Org: User:
Start: 05/01/24 End: 12/31/25 Due: 12/31/26

Adult Idiopathic Inflammatory Myopathy With Cardiac Injury

Phase: N/A Priority: Normal
NCT ID: NCT05982041 Org: User:
Start: 01/01/24 End: 01/01/43 Due: 01/01/44

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Phase: N/A Priority: Normal
NCT ID: NCT05743959 Org: User:
Start: 05/01/22 End: 12/30/25 Due: 12/30/26

The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)

Phase: N/A Priority: Normal
NCT ID: NCT06335836 Org: User:
Start: 03/01/24 End: 12/30/28 Due: 12/30/29

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06375707 Org: User:
Start: 01/09/24 End: 12/31/25 Due: 12/31/26

Relationship Between Lymph Node Dissection and Prognosis in High-risk NMIBC

Phase: N/A Priority: Normal
NCT ID: NCT05123625 Org: User:
Start: 07/01/21 End: 06/30/28 Due: 06/30/29

Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04956146 Org: User:
Start: 02/02/22 End: 09/30/24 Due: 09/30/25

the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

Phase: N/A Priority: Normal
NCT ID: NCT05032937 Org: User:
Start: 10/13/21 End: 01/05/23 Due: 01/05/24

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05334147 Org: User:
Start: 04/15/22 End: 09/01/25 Due: 09/01/26

Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

Phase: N/A Priority: Normal
NCT ID: NCT06080256 Org: User:
Start: 12/30/23 End: 12/31/24 Due: 12/31/25

The Effect of Automated Electronic Alert for Acute Kidney Injury on the Outcomes of Hospitalized Patients

Phase: N/A Priority: Normal
NCT ID: NCT03736304 Org: User:
Start: 08/01/19 End: 01/31/22 Due: 01/31/23

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05494060 Org: User:
Start: 03/16/22 End: 02/28/27 Due: 02/28/28

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05493683 Org: User:
Start: 08/01/22 End: 07/31/25 Due: 07/31/26